The science of education.
Current Courses Available - NON CE
Adult Survivorship
Fertility Preservation in Adult Cancer Patients
Damary C. Torres, PharmD, BCOP
Psychosocial Issues
Rowena N. Schwartz, PharmD, BCOP
Learning Objectives
1. Discuss methods to preserve fertility in adult cancer patients
2. Identify potential psychosocial issues and needs of adult cancer survivors
As presented at HOPA 2010, March 25th, 2010 in New Orleans, LA.
Controversies in Care: Hematology (Cases)
ALL: Pediatric vs Adult Regimens in AYA Population
Brooke Bernhardt, PharmD, BCOP
APL: Omission of Anthracyclines from Front-Line Treatment
Lindsay Hladnik, PharmD, BCOP
HIV Related Lymphoma: Optimal Timing and Selection of HAART Regimen
Kathlene A. DeGregory, PharmD, BCOP
Learning Objectives
1. State recent trends in managing adolescent and young adult patients with newly diagnosed ALL, focusing on criteria that assists in the selection of a traditional adult-based regimen versus a pediatric-inspired regimen.
2. Discuss the pros and cons of initiating front-line therapy with an ATRA and arsenic-based regimen versus an ATRA and anthracycline-based regimen.
3. Discuss the optimal timing and selection of an appropriate HAART regimen in patients with HIV-related lymphoma.
As presented at HOPA 2010, March 25th, 2010 in New Orleans, LA.
Controversies in Care: Solid Tumors (Cases)
Role of Maintenance/Early Second-Line Therapy for Advanced NSCLC
Leigh M. Boehmer, PharmD
Breast: Controversies in the Management of Triple-Negative Breast Cancer
Chad M. Barnett, PharmD, BCOP
Colorectal Cancer
Patrick J. Medina, PharmD, BCOP
Learning Objectives
1. Discuss recent data regarding maintenance/early second-line treatment of advanced NSCLC in order to identify the most appropriate treatment options.
2. Recognize the recurrence risk for early stage triple negative breast cancer.
3. Describe the optimal management strategies for early stage triple negative breast cancer.
4. Explain the pros and cons of continuing bevacizumab beyond tumor progression in patients with metastatic colon cancer.
As presented at HOPA 2010, March 25th, 2010 in New Orleans, LA.
Credentialing and Chemotherapy Preparation: A Technical Update
Chemotherapy Preparation: Competent and Confident
LeAnne Kennedy, PharmD, BCOP
Chemotherapy Preparation: The Impact of Closed System Transfer Devices
Ryan A. Forrey, PharmD, MS
Learning Objectives
1. Identify the methods to document the critical competencies required by technicians to process chemotherapy orders.
2. Discuss the advantages and disadvantages of closed system devices and various types of automation available to assist with the preparation of chemotherapy.
As presented at HOPA 2010, March 25th, 2010 in New Orleans, LA.
John G. Kuhn Keynote Lecture: Healthcare Reform – What Does It Mean for Oncology?
Joseph S. Bailes, MD
As presented at HOPA 2010, March 25th, 2010 in New Orleans, LA.
New Cytotoxic Chemotherapy Agents Approved for Metastatic Breast Cancer and Hormone Refractory Prostate Cancer
Michael J Berger, PharmD
Sherry Mori Vogt, Specialty Practice Pharmacist
Learning Objectives:
1. Describe the role of eribulin in the treatment of metastatic breast cancer (MBC) As presented via webcast, February 9, 2011
2. Discuss the need for dosage adjustment in hepatic and renal dysfunction
3. Illustrate the appropriate management of the dose limiting toxicities identified for eribulin
4. Dewscribe cabazitaxel and its role in the treatment of metastatic hormone refractory prostate cancer(HRPC)
5. Discuss the appropriate dosage of cabazitaxel in combination with prednisone
6. Illustrate strategies for managing adverse events associated with cabazitaxel
New Drug Update 2010 – Investigational Products
Theresa A. Mays, BS, PharmD, BCOP, FASHP
Learning Objectives
1. Discuss current and emerging pathways targeted in anticancer drug development strategies.
2. Describe recent clinical findings for newly developed therapies.
As presented at HOPA 2010, March 25th, 2010 in New Orleans, LA.
Risk Evaluation and Mitigation Strategies (REMS)
Niesha Griffith, MS, RPh, FASHP
Learning Objectives
1. Discuss the elements and implications of risk evaluation and mitigation strategy (REMS) programs in oncology pharmacy practice.
As presented at HOPA 2010, March 25th, 2010 in New Orleans, LA.